Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jinju Guk"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: While vancomycin remains a widely prescribed antibiotic, it can cause ototoxicity and nephrotoxicity, both of which are concentration-associated. Overtreatment can occur when the treatment lasts for an unnecessarily long time. Using a m
Externí odkaz:
https://doaj.org/article/73e1640888414b74a594e7348cb6de80
Autor:
Jinju Guk, Antoine Bridier‐Nahmias, Mélanie Magnan, Nathalie Grall, Xavier Duval, Olivier Clermont, Etienne Ruppé, Camille d'Humières, Olivier Tenaillon, Erick Denamur, France Mentré, Jérémie Guedj, Charles Burdet, for the CEREMI study group
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 7, Pp 906-918 (2022)
Abstract Recent studies have highlighted the importance of ecological interactions in dysbiosis of gut microbiota, but few focused on their role in antibiotic‐induced perturbations. We used the data from the CEREMI trial in which 22 healthy volunte
Externí odkaz:
https://doaj.org/article/f98f42159e9d4ed9864a215afe0ec81c
Publikováno v:
Journal of Pharmaceutical Sciences. 108:2765-2773
Phenytoin has been decreasingly used because of the high interindividual variability in drug concentration and the narrow therapeutic window. Despite such drawbacks, phenytoin is still essential as a second-line therapy for status epilepticus when pa
Autor:
Jinju Guk, Jérémie Guedj, Charles Burdet, Antoine Andremont, Jean Gunzburg, Annie Ducher, France Mentré
Publikováno v:
Clinical pharmacology and therapeutics. 109(4)
To prevent antibiotic-induced perturbations on gut microbiota, DAV132, a novel colon-targeted adsorbent, which sequesters antibiotic residues in the lower gastrointestinal tract, was developed. We built an integrated pharmacological model of how DAV1
Publikováno v:
Translational & Clinical Pharmacology. Jun2017, Vol. 25 Issue 2, p101-105. 5p.
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 120:270-277
Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food. However, the pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood. Th
Publikováno v:
Clinical Therapeutics. 38:1845-1857
Purpose Rosuvastatin, a hydroxy methylglutaryl coenzyme A reductase inhibitor; telmisartan, an angiotensin receptor blocker; and amlodipine, a calcium channel inhibitor, are commonly prescribed together for the treatment of hypertension nonresponsive
Aims Recombinant tissue plasminogen activator (rt-PA) is the only first-line agent approved by the US Food and Drug Administration to treat acute ischaemic stroke. However, it often causes the serious adverse event (AE) of haemorrhagic transformation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ed424fdb96b4ef8b8e3e0012ff38cf
https://europepmc.org/articles/PMC6177699/
https://europepmc.org/articles/PMC6177699/
Autor:
Jinju Guk, Hyerang Roh, Su Youn Nam, Yukyung Kim, Mijeong Son, Kyungsoo Park, Donghwan Lee, Hankil Son, Seong Bok Jang
Publikováno v:
Clinical Therapeutics. 36:1147-1158
Purpose Rosuvastatin is indicated for hypercholesterolemia or dyslipidemia and metformin mainly for type 2 diabetes. These 2 drugs are frequently prescribed in combination due to the high comorbidity of the 2 diseases. However the nature of pharmacok
Publikováno v:
International journal of clinical pharmacology and therapeutics. 54(9)
UNLABELLED OBJECTIVE The conventional suspension of megestrol acetate contains micronized megestrol acetate, which was recently discovered to have a disadvantage of decreasing bioavailability when taken in a fasting state. Since megestrol acetate is